show episodes
 
The podcast of the American College of Clinical Pharmacy (ACCP). Offers interviews about a variety of clinical topics, interviews with influencers in clinical pharmacy, and overview of various research topics.
 
Loading …
show series
 
In this 30-minute podcast, Peter Simons reports on the latest scientific articles in psychiatry. The goal is to provide more detail than is usually found in conventional research news and to help listeners understand how to interpret the findings. Articles covered in this podcast include: How the mental health app Cerebral is facing accusations of …
 
Where do you see yourself in 10 years? The ACCP Resident Advisory Committee assembled a panel representing four career paths and advice on how to get there. This podcast focuses on career advice for the early practitioner. Moderated by Henry Okoroike, guests include: Deborah Bondi, Elias Chahine, Christina Doligalski, and Alexander Flannery. 0:00 –…
 
Where do you see yourself in 10 years? The ACCP Resident Advisory Committee assembled a panel representing four career paths and advice on how to get there. This podcast focuses on how involvement in ACCP contributed to the panelists professional development. Moderated by Henry Okoroike, guests include: Deborah Bondi, Elias Chahine, Christina Dolig…
 
In this 30-minute podcast, Peter Simons reports on the latest scientific articles in psychiatry. The goal is to provide more detail than is usually found in conventional research news and to help listeners understand how to interpret the findings. Articles covered in this podcast include: Researchers write that “psychology is fundamentally incompat…
 
Peter Simons covers a study in Nature finding that the positive results of psychiatry’s brain imaging studies are false; a study demonstrating that more than half of negative antidepressant trials remain unpublished or are misleadingly “spun” as positive; an article that may explain why some people don’t find meditation to be helpful; and more! Nat…
 
Peter Simons covers a study that found both therapy and medication to have very limited effectiveness; an article suggesting that general practitioners need to prescribe fewer antidepressants; a study that concluded no brain imaging test has been able to identify a meaningful brain difference in depression; and more! Major Review Finds Limited Effe…
 
Peter Simons covers a clinical trial that found lithium ineffective at preventing suicide attempts, an essay by Allen Frances on the overdiagnosis of depression and overprescription of antidepressants, a review of the ineffectiveness and dangers of antidepressants, and an analysis that revealed that esketamine failed five of its six clinical trials…
 
Peter Simons covers articles about the validity of psychiatric diagnoses, the medicalization of normal human experiences like grief, and how the pharmaceutical industry co-opts feminist messaging to gain approval for ineffective drugs. Kenneth Kendler: “Implausible” That Psychiatric Diagnoses Even “Approximately True” Neurobiological Explanations C…
 
This week, Peter Simons covers a study about the controversial practice of placebo run-in periods in antidepressant studies, a study about withdrawal symptoms being mistaken for relapse, and a book chapter that addresses stigma and discrimination. Researchers Push to End Placebo Run-in Periods in Antidepressant Studies Withdrawal Symptoms Cloud Fin…
 
This week, Peter Simons covers studies examining whether mental health literacy and essentialist thinking are associated with stigma against those with mental health problems. He also covers a study finding that psychotherapy is ineffective for the majority of children with depression. Mental Health Literacy Does Not Reduce Stigma, Psychosocial App…
 
This week, Peter Simons covers a study that found prolactin-increasing antipsychotics associated with increased breast cancer risk, an analysis that found no convincing evidence that screening for depression improves outcomes, and the continuing controversy around the FDA's approval of Biogen's failed Alzheimer's drug aducanumab. Antipsychotics Lin…
 
This week, Peter Simons covers studies on the biological mechanism behind antipsychotic drugs' association with dementia; surprising brain imaging findings with implications for antidepressant effectiveness; bias in the psychotherapy literature; and the trauma caused by involuntary treatment of people with psychosis. Antipsychotics Increase Risk of…
 
This week, Peter Simons covers three studies about financial ties to the pharmaceutical industry in editorial and commentary writers in medical journals. These conflicts of interest create biased research literature that helps pharma push potentially harmful and less effective drugs. Conflicts of Interest Linked to“Unduly Favorable” Editorials Conf…
 
This week, Peter Simons covers two articles about the pharmaceutical industry's influence on drug regulators, and an article finding that newborn babies experience antidepressant withdrawal if their mothers took SSRIs while pregnant. 75% of Pharma Companies Fail Basic Transparency Measures How to Address the Undermining of Drug Regulators by Pharma…
 
This week, Peter Simons covers three new articles which suggest that “relapse” in the drug trials for both antidepressants and antipsychotics is likely caused by sudden withdrawal. This contradicts the notion that the drugs have protective effects against relapse. “Relapse” in Antidepressant Trials Likely Caused by Sudden Withdrawal Sudden Antipsyc…
 
Loading …

Quick Reference Guide

Copyright 2022 | Sitemap | Privacy Policy | Terms of Service
Google login Twitter login Classic login